Bioporto ASTHOXF 66 Interest Coverage is 0 (At Loss) as of Dec. 2025. GuruFocus rates THOXF with a GF Score™ of 66/100 and a GF Value™ of $0.17. The stock has 3 warning signs investors should review. Among 94 Medical Diagnostics & Research companies, Bioporto AS ranks worse than 1063828.72% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Bioporto AS's
Operating Income
for the
three
months ended in Dec. 2025 was $-2.19 Mil. Bioporto AS's Interest Expense for the
three
months ended in Dec. 2025 was $0.32 Mil.
did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Bioporto AS's Interest Coverage or its related term are showing as below:
THOXF's Interest Coverage is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 9.155 * Ranked among companies with meaningful Interest Coverage only.
Bioporto AS (OTCPK:THOXF) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Bioporto AS Interest Coverage Related Terms
Bioporto AS Interest Coverage Historical Data
* Premium members only.
The historical data trend for Bioporto AS's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
THOXF vs TMO, DHR, IDXX: Interest Coverage Comparison
For the Diagnostics & Research subindustry, Bioporto AS's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioporto AS Interest Coverage vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Bioporto AS's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Bioporto AS's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of 0 (At Loss) mean?
Bioporto AS (THOXF) has a Interest Coverage of 0 (At Loss) as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Bioporto AS and its competitors. According to the industry distribution chart, Bioporto AS ranks #999999 out of 94 companies in the Medical Diagnostics & Research industry.
Is Bioporto AS's Interest Coverage too high?
Bioporto AS's current Interest Coverage is 0 (At Loss). Based on the distribution chart, Bioporto AS ranks #999999 out of 94 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Bioporto AS has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does Bioporto AS's Interest Coverage compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Bioporto AS ranks #999999 out of 94 companies for Interest Coverage. This places Bioporto AS in the lower half of its industry. The industry median Interest Coverage is 9.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Diagnostics & Research company?
The median Interest Coverage among Medical Diagnostics & Research companies is 9.16, based on 94 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Bioporto AS and its competitors. For the Medical Diagnostics & Research industry, the median Interest Coverage is 9.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioporto AS's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioporto AS stock overvalued right now?
Bioporto AS (THOXF) has a current Interest Coverage of 0 (At Loss). The stock's GF Value™ is $0.17, compared to a current price of $0.15 — trading 12.4% below its estimated fair value. The current Interest Coverage is 0 (At Loss). Bioporto AS's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Bioporto AS (THOXF), the current Interest Coverage is 0 (At Loss) as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioporto AS (THOXF) Overvalued in 2026?
Based on GuruFocus' analysis, Bioporto AS stock appears to be undervalued.
The current stock price of $0.15 is trading 12.4% below its estimated GF Value™ of $0.17.
Key valuation signals for THOXF:
Interest Coverage: 0 (At Loss)
GF Value™: $0.17 vs. price of $0.15 (12.4% below fair value)
No single metric tells the full story. See the THOXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioporto AS is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America. Geographically, its business area is in North America, Denmark, and rest of Europe, and Asia. The products of the company involve: ProNephro AKI, The NGAL Test, Antibodies, ELISA Kits, gRad Lateral Flow, and others.
66GF Score
Get the complete analysis for THOXF
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
THOXF has been successfully added to your 
